Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4262]

SABCS 2012: Extending adjuvant trastuzumab treatment time provided no additional benefit

SABCS 2012: Extending adjuvant trastuzumab treatment time provided no additional benefit

Women with higher carotenoid levels have reduced risk of breast cancer

Women with higher carotenoid levels have reduced risk of breast cancer

$SABCS 2012: Hypofractionated radiotherapy was safe, effective for early breast cancer treatment at 10-year follow-up$

SABCS 2012: Hypofractionated radiotherapy was safe, effective for early breast cancer treatment at 10-year follow...

SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin...

SABCS 2012: Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemotherapy

SABCS 2012: Diverse genetic alterations found in triple-negative breast cancers after neoadjuvant chemotherapy

SABCS 2012: Young women with breast cancer were more likely than older women to respond to neoadjuvant chemotherapy

SABCS 2012: Young women with breast cancer were more likely than older women to respond to neoadjuvant chemotherapy

SABCS 2012: Chemotherapy after complete surgical removal of local or regional breast cancer recurrence increased survival rates

SABCS 2012: Chemotherapy after complete surgical removal of local or regional breast cancer recurrence increased...

SABCS 2012: Study confirms fewer, bigger doses of radiotherapy benefit cancer patients

SABCS 2012: Study confirms fewer, bigger doses of radiotherapy benefit cancer patients

SABCS 2012: Black women less likely to receive improved surgical procedure for breast cancer

SABCS 2012: Black women less likely to receive improved surgical procedure for breast cancer

SABCS 2012: Extending duration of adjuvant tamoxifen treatment to 10 years reduced risk for late breast cancer recurrence, improved survival

SABCS 2012: Extending duration of adjuvant tamoxifen treatment to 10 years reduced risk for late breast cancer...

More from ecancer